You just read:

SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp

News provided by

SCYNEXIS, Inc.

Oct 23, 2018, 09:00 ET